NuPathe Inc., a Conshohocken, Penn.-based drug startup focused on neurological and psychiatric disorders, has raised $30 million in Series B funding. Quaker BioVentures and S.R. One Ltd. co-led the round, and were joined by return backers Safeguard Scientifics, Bay City Capital/Birchmere Ventures, Battelle Ventures and BioAdvance Ventures
NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced that the company has raised $30 million in a recently completed Series B equity financing. The financing was led by investments from two top venture capital funds: Quaker BioVentures and SR One Ltd., the venture capital arm of GSK. Previous investors, Safeguard Scientifics, Inc (NYSE:SFE), Bay City Capital/Birchmere Ventures, Battelle Ventures and BioAdvance Ventures participated in the round. Michael C. Diem, M.D., principal at SR One Ltd. will join NuPathe's board of directors.
“The Series B financing represents a significant milestone for NuPathe and comes at an exciting time for our company,” said Jane Hollingsworth, chief executive officer and co-founder of NuPathe Inc. “NuPathe is now in a position to optimize the development and commercialization of NP101, a unique treatment for acute migraine, as well as NP201, a novel product for Parkinson's disease. We are grateful to have such highly regarded investors guiding our growth and providing the support we need to advance the treatment of some of the most devastating neurological and psychiatric diseases.”
Mark Pierce M.D., Ph.D., chief scientific officer of NuPathe said, “It is indeed an exciting time at NuPathe. We recently presented positive Phase I results for NP101 at the Annual Scientific Meeting of the American Headache Society demonstrating that NP101 delivers sumatriptan in a rapid, predictable, and consistent manner. Large Phase III clinical trials are being initiated now to evaluate the safety and efficacy of NP101.”
“NuPathe's success to date has been extraordinary and we are very confident about the future,” said Richard S. Kollender, partner at Quaker BioVentures. “NP101 provides NuPathe with a powerful vehicle to become a leading specialty pharmaceutical company. We are looking forward to working with NuPathe on this journey.”
“We are impressed with the leadership and focus of Jane and her management team, particularly with the progress they have made in the development of the lead product and pipeline,” said Michael C. Diem, M.D., principal at SR One Ltd.
NuPathe Inc. is a specialty pharmaceutical company developing innovative therapeutic products for the treatment of neurological and psychiatric diseases. NuPathe's mission is to identify and address the needs of patients that are insufficiently met by current treatments. NuPathe's product portfolio includes NP101, which, if approved, will be the first and only transdermal patch for the treatment of acute migraine, and NP201, a long acting injectable implant for the treatment of Parkinson's disease. Please visit NuPathe's web site at www.nupathe.com.
NP101 is a novel drug-device patch in clinical development for acute migraine. Today, only 50% of migraine patients are satisfied with their migraine treatment due to issues such as migraine-associated nausea/vomiting, inconsistent relief, and side-effects. NP101 was designed to address these issues, which may provide patients with improved ability to take control over their migraine as compared to currently available oral and non-oral options. NP101 is based on NuPathe's proprietary SmartRelief